金山科研平台，产品价格货期咨询微信：jinshanbio Source:Mouse myeloma cell line, NS0-derived Accession #:Q53SV1 N-terminal Sequence Analysis:Asp23 Structure:Disulfide-linked homodimer Purity:>95%, by SDS-PAGE under reducing conditions and visualized by silver stain. Endotoxin Level: Predicted Molecular Mass:39 kDa (monomer) SDS-PAGE:40-45 kDa, reducing conditions Activity:Measured by its binding ability in a functional ELISA.When recombinant human BMP-6 (Catalog # 507-BP)is used at 0.25µg/mL, the concentration ofrecombinant human Activin R1A Fc chimerathat produces 50% of the optimal binding responseis found to be approximately1 - 5 µg/mL. Formulation:Lyophilized from a 0.2 µm filtered solution in PBS.See Certificate of Analysis for details. Molecule Information: Activin RIA/ALK-2 Long Name: Activin Receptor IA Aliases: ACVR1; ALK-2 Entrez Gene IDs: 90 (Human) Background: Activin Receptors Receptors for the TGF-beta superfamily comprise two groups, the type I and the type II serine/threonine kinases. These kinases are type I transmembrane proteins, and the two subgroups are distinguished by the presence of a glycine/serine-rich juxta-membrane domain found in the type I receptors. Either a type I or type II receptor may initially bind ligand, followed by recruitment of its alternate-type receptor counterpart to generate a heteromeric signaling complex. Type I receptors are referred to as the Activin Receptor-like Kinases (ALKs), while the type II receptors are named for the ligands they bind.